Predictive Analysis in Biotech

Sat, 11 Jan 2025 00:00:00 +0000

Evaluating the mechanism of action (MOA) of therapeutic targets, specifically differentiating between upstream and downstream interventions. Systematically analysing how the position of a target within a biological pathway influences the probability of success (POS). For example, if a biotech company targets RAS mutations in pancreatic cancer but the primary oncogenic drivers occur downstream of RAS in the signalling cascade, the target is less likely to succeed in trials. Upstream targets, often involved in early signalling processes, present unique challenges and opportunities compared to downstream targets, which tend to be closer to the therapeutic outcome. Understanding these distinctions allows for a more accurate prediction of clinical trial outcomes, regulatory approval likelihood, and eventual market performance. Let’s dive into how predictive analysis reshapes biotech equities, delve into the intricacies of upstream versus downstream MOAs, and discuss how this innovative approach reshapes the investment landscape in the biotechnology sector.

Factors Influencing Probability of Success (POS)

Target Biology and MOA

Understanding the biological context of a therapeutic target is foundational. Upstream targets, like transcription factors or signalling regulators, can disrupt entire pathways but often face redundancy due to compensatory mechanisms. These targets frequently suffer from poor druggability due to structural challenges or lack of surface binding pockets. Conversely, downstream targets—closer to the disease phenotype—are more actionable, offering measurable biomarkers but posing risks of off-target effects due to their proximity to cellular machinery critical for normal functions.

Investing on Stephanie Rebecca

Predictive Analysis in Biotech

Factors Influencing Probability of Success (POS)

Target Biology and MOA